论文部分内容阅读
据报道1994～95年,wellcome 公司的新产品开发可能要占总销售的20%,利润的30%,但从销售潜力的角度来看公司的抗病毒药阿昔洛韦(aciclovir,zovirax)并无明显优势,说明在美国药品的定价问题对于研究与开发的影响愈来愈明显。
It is reported that from 1994 to 1995, wellcome’s new product development may account for 20% of total sales and 30% of profits, but the company’s antiviral drug aciclovir (zovirax) from the point of view of sales potential No obvious advantage, indicating that the pricing of drugs in the United States for research and development impact more and more obvious.